Corporate presentation – June 2013

Updated for June 2013, Invion’s investor presentation provides an overview of the Company’s current activities, including:

  • phase II clinical trials of INV102 (nadolol) in asthma and chronic bronchitis;
  • the phase II development of INV103 (ala-Cpn10) as a potential therapy for lupus; and,
  • Invion’s expected value drivers over the next 12 – 36 months
Posted in Presentations